#9: ILC2s and cancer

Cutting-edge approaches to combat tumor development involve transplantation of anti-tumor T cells and natural killer cells. Natural killer (NK) cells belong to a greater family of innate lymphoid cells which includes the more recently described group 1, 2, and 3 innate lymphoid cells (ILCs). Unlike NK and T cells, the role of non-NK ILCs in tumor immunity remains unclear. In this episode, Kellen highlights a 2020 report in Nature describing the role of ILC2s in pancreatic cancer. The article was written by John Alec Moral and colleagues and is titled “ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity”.

Paper: https://www.nature.com/articles/s41586-020-2015-4

Review: https://pubmed.ncbi.nlm.nih.gov/30209347/

To help us spread science, please consider writing a review, sharing this episode with your friends and colleagues, or donating to support our work (Venmo @Kellen-Cavagnero).

Please reach out to us via email (kcavagnero@gmail.com) or Twitter (@KellenCavagnero) with any questions, comments, topic suggestions, etc.